Stallergenes Greer

Since its inception in 1962, Stallergenes has been significantly contributing to the development of allergen immunotherapy and is highly committed to innovation to improve its patients' quality of life.

Based on this concept, our mission was to create a direct and accurate communication.
Formal vocabulary has been defined based on several innovative pieces, which address the company's needs and demands within a competitive and expanding market.